தேசிய அவசியம் மருந்துகள் பட்டியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 13, 2021 Jiuquan, China, April 13, 2021 (GLOBE NEWSWIRE) Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that 16 of its products have been included in the latest version of the National Reimbursement Drugs List in China, such as aspirin enteric-coated tablets for coronary heart disease treatment, and nitrofurantoin enteric-coated tablets for the treatment of urinary tract infections. In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China. National Reimbursement Drug List is the list of products eligible for reimbursement in China, as maintained by the National Healthcare Commission of China. The National Essential Medicines List is one of the core contents of the essential medicines system. The system requires that all government-run primary health care institutions be equi

Zhanchang xinTina xiaoAscent investors relationsNational essential medicines listChina national healthcare security administrationNational healthcare commission of chinaQilian international holding groupNational reimbursement drug listQilian international holding group limited nasdaqNational reimbursement drugs listInternational holding group limitedReimbursement drug listNational healthcare commissionNational healthcare security administrationTeva pharmaceutical austedoPrivate securities litigation reform act